- Home
- PTHL vs TLPH Comparison
PTHL vs TLPH Comparison
Compare PTHL & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTHL
- TLPH
- Stock Information
- Founded
- PTHL 1998
- TLPH 2005
- Country
- PTHL China
- TLPH United States
- Employees
- PTHL N/A
- TLPH N/A
- Industry
- PTHL
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- PTHL
- TLPH Health Care
- Exchange
- PTHL Nasdaq
- TLPH Nasdaq
- Market Cap
- PTHL 13.5M
- TLPH 11.1M
- IPO Year
- PTHL 2024
- TLPH 2011
- Fundamental
- Price
- PTHL $0.91
- TLPH $0.98
- Analyst Decision
- PTHL
- TLPH Strong Buy
- Analyst Count
- PTHL 0
- TLPH 1
- Target Price
- PTHL N/A
- TLPH $6.00
- AVG Volume (30 Days)
- PTHL 1.8M
- TLPH 7.3M
- Earning Date
- PTHL 01-01-0001
- TLPH 11-12-2025
- Dividend Yield
- PTHL N/A
- TLPH N/A
- EPS Growth
- PTHL N/A
- TLPH N/A
- EPS
- PTHL N/A
- TLPH N/A
- Revenue
- PTHL $448,196.00
- TLPH $27,000.00
- Revenue This Year
- PTHL N/A
- TLPH N/A
- Revenue Next Year
- PTHL N/A
- TLPH $14,533.26
- P/E Ratio
- PTHL N/A
- TLPH N/A
- Revenue Growth
- PTHL N/A
- TLPH N/A
- 52 Week Low
- PTHL $0.51
- TLPH $0.38
- 52 Week High
- PTHL $32.00
- TLPH $1.20
- Technical
- Relative Strength Index (RSI)
- PTHL 30.66
- TLPH 82.15
- Support Level
- PTHL $0.82
- TLPH $0.40
- Resistance Level
- PTHL $0.98
- TLPH $1.20
- Average True Range (ATR)
- PTHL 0.17
- TLPH 0.13
- MACD
- PTHL 0.53
- TLPH 0.05
- Stochastic Oscillator
- PTHL 55.65
- TLPH 68.57
About PTHL Pheton Holdings Ltd Class A Ordinary Shares
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.